Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation

Fig. 2

Biological activity of EE02 in vitro. a The expression levels of EGFR and EPS8 in different cell lines are shown. b A549, H460, BT549 and MCF-7 cells were seeded and treated with increasing concentrations of EE02 for 2 weeks. Colonies were counted, and images were acquired. The quantification of the colony numbers is shown. c Cancer cell lines were treated with EE02 for 24 h at increasing concentrations (0, 1, 2.5, 5, 7.5 and 10 μM), and then cell viability was assessed using CCK-8 assays (n = 3). d PBMCs from 5 untreated healthy donors were treated with increasing concentrations (0, 1, 2.5, 5, 7.5 and 10 μM) of EE02 for 24 h, and cell viability was analyzed via CCK-8 assays (n = 3). e Normal cell lines were treated with EE02 for 24 h at increasing concentrations (0, 1, 2.5, 5, 7.5 and 10 μM), and then cell viability was assessed using CCK-8 assays (n = 3)

Back to article page